

Page 1 redacted in full under section 22(1) of the FOI Act (irrelevant information)

CONTENTS

SECTION 1 Chronological correspondence file commencing 30 July 1993 to 23 December 1993.

SECTION 2 Individual details of nine adverse events each identified by study number.

SECTION 3 Study Protocol 356.

SECTION 4 Correspondence of Investigators notifying Ethics Committees by centre.

SECTION 5 Monitors file notes for [REDACTED]

SECTION 6 Correspondence with Worldwide Product Safety in the UK concerning suicides in protocol 356.

SECTION 7 Correspondence from [REDACTED], Aropax Review Board Member and recognised Australian authority on suicides in depression.

PAROXETINE 356 SERIOUS ADVERSE EVENTS

| PATIENT # | INVESTIGATOR | EVENT | SAE EVENT DATE | MLS/SB AUST NOTIFIED | SB UK | CEN/AEGIS NUMBER |
|-----------|--------------|--------------------------|----------------|----------------------|------------|------------------|
| s22(1) | [REDACTED] | [REDACTED] | [REDACTED] | [REDACTED] | [REDACTED] | [REDACTED] |
| s22(1) | [REDACTED] | SUICIDES47F [REDACTED] ⊗ | [REDACTED] | [REDACTED] | [REDACTED] | [REDACTED] |
| s22(1) | [REDACTED] | SUICIDES47F [REDACTED] ⊗ | [REDACTED] | [REDACTED] | [REDACTED] | [REDACTED] |

* SUICIDE ATTEMPT

⊗ SUICIDES

[REDACTED]

[REDACTED]